NSE: MANKIND · 29 September 2026 · Dated market coverage
- The stock is +4.49% at ₹2,545.00.
- Likely reason:Stock-specific buying and volume surge
- Approximate traded value is₹500.81 crore.
- It is -3.67% from its 52-week high and +33.27% from its 52-week low.
- The stock is being compared withNifty Pharmaalongside the Nifty 50.
Why Is Mankind Pharma Share Price Rising Today?
Latest NSE EOD report: 2026-09-29. Today’s Volume: 1,967,833; 5-Day Avg. Volume: 699,166; 20-Day Avg. Volume: 472,398; Volume vs 20-Day Avg.: 4.17x; Delivery Quantity: 697,782; Delivery %: 35.35%; Number of Trades: 84,454.
Mankind Pharma shares advanced notably in today’s session, gaining 4.49% to close at ₹2,545.00. The stock opened at ₹2,440.40 and touched an intraday high of ₹2,557.60, operating near the upper bound of its daily price band. Trading activity spiked significantly, with volume surging to 2.81 times its 5-day average and 4.17 times its 20-day average, accompanied by a healthy delivery percentage of 35.35%.
In relative terms, Mankind Pharma outperformed the broader market and outpaced its sectoral benchmark. While the benchmark Nifty index slipped by 0.28%, the Nifty Pharma sector gained a modest 0.64%, reflecting strong buying interest centered specifically on Mankind against a flat-to-negative broader market backdrop.
On the corporate and news front, the company recently announced the resignation of the statutory auditors of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited, following earlier board consent for its voluntary liquidation and integration into the parent company. While these administrative restructuring updates provide backdrop context, today’s sharp price momentum and high trading volume appear primarily driven by strong stock-specific accumulation and buying interest.
medium confidence
- Intraday gain of 4.49% with price closing near the day’s high of ₹2,557.60
- Volume surged to 4.17 times the 20-day average
- Outperformed Nifty’s decline of 0.28% and Nifty Pharma’s gain of 0.64%
Ownership & Transaction Activity
Completion of Realignment of Security Cover in respect of Non-ConvertibleDebentures and Consequent Release of Pledged Shares of Bharat Serums andVaccines Limited
Source: NSE corporate filing
- Promoter group submitted compliance disclosures under Regulation 31(4) of SEBI SAST Regulations confirming zero encumbrances for FY ending March 31, 2026.
- Ramesh Juneja, Rajeev Juneja, and Sheetal Arora are listed among the key promoter and promoter group entities.
Source: NSE corporate disclosure. Only factual ownership/shareholding details extracted from the filing are shown.
WittyTrades Data Insight
Price Position:The stock is near the upper end of the day’s trading range.
Move From Open:+4.29%.
Intraday Range:4.81% of the previous close.
5-Day Performance:+2.62%; 20-Day Performance:+8.00%.
Latest Company Developments
What Should Traders and Investors Watch Next?
- Progress and regulatory approvals regarding the voluntary liquidation and integration of Bharat Serums and Vaccines Limited
- Commercialization updates on the newly in-licensed insulin products in the anti-diabetic segment
- Sustained delivery volumes and price stability above key moving averages
- Upcoming financial results and management commentary on chronic therapy margins
Catalyst note:No single same-day catalyst was officially announced to directly trigger today’s surge, which appears driven by strong institutional or retail accumulation and volume expansion.
Frequently Asked Questions
What is the likely reason for today’s move?
The stock rallied 4.49% on significantly elevated trading volume (over 4x its 20-day average), outperforming both the broader Nifty and Nifty Pharma indices. While recent corporate restructuring updates regarding its subsidiary provide context, the sharp price movement reflects strong underlying buying interest.
Is trading volume elevated?
Today’s volume is 1,967,833. The latest 20-day average available is 472,398, equivalent to about 4.17x of the recent average.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review theWittyTrades subscription plans and research segments.
Article by:WittyTrades Research Desk